Ken Waggoner joined Nuvilex, now PharmaCyte in November 2013. The questions he was answering were regarding the April 2013 10k. What this confirms for me is that we are very lucky that he took over this company. He has done an amazing job to get us where were are today. I am very thankful to have him as our CEO and know that he has made some major changes since coming on board which are only to our benefit.
This doesn't tell me anything keep digging bro....lol. fda approved cell in box for ODD...CEO of td2 likes cell in box...CEO of CNS likes cell in box...anne simpson put her lifes work for diabetes in pmcb hands...that's all you need to know.....clinical trials up next for pancreatic cancer....let the good times roll.
This is very typical to have the sec comment on statements made.
My last company that I took public hd 5 rounds of comments from the sec prior to us being allowed to file our S1. Typically there are 50-60 SEC comments the first round and there are usually 3-5 rounds of comments until the SEC is satisfied
News 
Market Data 
Discover 
AI
